Scatter plot of incremental cost against QALY gained by EGFR mutation-guided afatinib versus empirical chemotherapy.
figureposted on 01.03.2021, 18:33 authored by Joyce H. S. You, William C. S. Cho, Wai-kit Ming, Yu-chung Li, Chung-kong Kwan, Kwok-hung Au, Joseph Siu-kie Au
QALY: quality-adjusted life-year; WTP: willingness-to-pay.
Read the peer-reviewed publication
WTPConclusions EGFR mutation-guided er...GDPEGFR mutation-guided useTKIepidermal growth factor receptorIIIBModel outcome measuresICERcost-effectiveness analysis Introdu...EGFR mutation-guided erlotinibstrategyun-tested EGFR-sensitizing mutation...Hong KongNSCLCQALYEmpirical first-line chemotherapyUSDnon-small-cell lung cancerResults Empirical chemotherapyEGFR mutation-guided gefitinibEGFR mutation-guided afatinibEGFR mutation-guided target therapy